Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma

Hepatology

Volumn 47, Issue 1, 2008, Pages 105-112

  Cui, Qiang ^a,b   Jiang, Wei ^a   Wang, Yingxin ^a   Lv, Chen ^a   Luo, Jingjing ^a   Zhang, Wei ^a   Lin, Fang ^a   Yin, Yuexiang ^a   Cai, Rong ^a   Wei, Ping ^b   Qian, Cheng ^a  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

^b NORTHEAST AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CELL PENETRATING PEPTIDE; CYCLIN D1; JANUS KINASE; ONCOLYTIC ADENOVIRUS; PROTEIN BCL XL; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; EMBRYO; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR GROWTH; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL DEATH; CELL LINE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; VIRUS REPLICATION;

EID: 38649136288     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21951     Document Type: Article

References (37)

1. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
2. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
3. Seki Y, Suzuki N, Imaizumi M, Iwamoto T, Usami N, Ueda Y, et al. STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. Int J Oncol 2004;24:931-934.
4. Clevenger CV. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004;165:1449-1460.
5. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003;100:4138-4143.
6. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002;109:1139-1142.
7. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
8. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-954.
9. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Ann Rev Immunol 2000;18:143-164.
10. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 2005;7:100-110.
11. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-1128.
12. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005;24:6406-6417.
13. Aghi M, Robert LM. Oncolytic viral therapies - the clinical experience. Oncogene 2005;24:7802-7816.
14. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene 2005;24:7775-7791.
15. Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res 2006;16:182-188.
16. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005;16:845-858.
17. Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. HEPATOLOGY 2004;39:1371-1381.
18. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-112.
19. Zou W, Luo C, Zhang Z, Liu J, Gu JF, Pei ZF, et al. A novel oncolytic adenovirus targeting to telomerase activity in tumot cells with potent. Oncogene 2004;23:457-464.
20. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002;62:4663-4670.
21. Rivera AA, Wang M, Suzuki K, Uil TG, Krasnykh V, Curiel DT, et al. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology 2004;320:121-134.
22. Joliot A, Prochiantz A. Transduction peptides: from technology to physiology. Nat Cell Biol 2004;6:189-196.
23. Mae M, Langel U. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol 2006;6:509-514.
24. Gusarova GA, Wang IC, Major ML, Kalinichenko W, Ackerson T, Petrovic V, et al. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest 2007;117:99-111.
25. Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, et al. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 2006;66:3764-3772.
26. Zender L, Kock R, Eckhard M, Frericks B, Gosling T, Gebhardt T, et al. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 2002;123:608-618.
27. Jo D, Liu D, Yao S, Collins RD, Hawiger J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med 2005;11:892-898.
28. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 2003;100:14133-14138.
29. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999;59:5059-5063.
30. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, et al. Constitutive activation of JAK3-STAT3 in colon carcinoma tumors and cell lines inhibition of JAK3-STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005;167:969-980.
31. Huang C, Gao J, Huang KJ, Zhang F, Jiang T, Zhu L, et al. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci 2006;97:1417-1423.
32. Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, et al. The synthetic triterpenoid CDDO-imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 2006;12:4288-4293.
33. Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005;65:2532-2536.
34. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in tegulation of the immune response. Annu Rev Immunol 2004;22:503-529.
35. Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 2006;131:179-193.
36. Ogata H, Chinen T, Yoshida T, Kinjyo I, Takaesu G, Shiraishi H, et al. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 2006;25:2520-2530.
37. Young CS. The structure and function of the adenovirus major late promoter. Curr Top Microbiol Immunol 2003;272:213-249.